Waxman alleges Troy blocked Plan B decision

Share this article:
Before he left the FDA 18 months ago, former chief counsel Dan Troy failed to complete a necessary legal review of Barr Laboratories' proposed under-16 sales restriction on over-the-counter Plan B, requested by FDA reviewers eight months earlier, according to a March 9 letter to the agency from Henry A. Waxman (D-CA).

Waxman's letter charges that the FDA set Barr up for Plan B's defeat by convincing it to amend its application to propose the under-16 restriction that it knew it would later call too “difficult and novel” to be approved without indefinite further consideration—“a regulatory Catch 22,” as Waxman called it.

His seven-page letter cited internal FDA e-mails suggesting Troy's office was repeatedly reminded of the need for the legal review and of its urgency due to a six-month statutory deadline on Barr's application, a deadline the FDA failed to meet. These documents “reveal that in addition to having created the situation it now protests as too complex to solve, FDA has seriously mischaracterized its consideration of the regulatory questions at stake,” Waxman wrote.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"